Induction therapies, particularly those that include polyclonal antibodies that deplete the lymphocyte pool, including CD4+ lymphocytes [73,74,75], are linked to a high risk of PCP during the first six months post-transplantation [76]. The gene discussed is CD4; the disease is pneumocystosis.